retatrutide liver nonalcoholic fatty disease nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide: A Promising Breakthrough for

More significant results accumulate over three to nine months, depending on dosing, adherence, and individual physiology

The main causes of this hair thinning are deficiencies in the following: Vitamin D Zinc Protein With a loss of appetite, many GLP-1 patients arent eating enough, and therefore not consuming the protein they need for essential body functions, including muscle strength , but also hair growth

similar mechanisms may apply

Stay optimistic

However, emerging research has explored potential indirect relationships between GLP-1 receptor agonist therapy and cortisol regulation

The additional GIP receptor activation contributes to its overall efficacy profile